BidaskClub upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a hold rating to a buy rating in a research report sent to investors on Thursday.

A number of other equities research analysts also recently commented on the company. Canaccord Genuity reiterated a buy rating on shares of Atara Biotherapeutics in a report on Thursday, November 9th. Jefferies Group reiterated a buy rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Citigroup upgraded Atara Biotherapeutics from a sell rating to a neutral rating and set a $18.00 price objective for the company in a report on Wednesday, January 3rd. Goldman Sachs Group reiterated a neutral rating and issued a $20.00 price objective on shares of Atara Biotherapeutics in a report on Friday, October 6th. Finally, ValuEngine upgraded Atara Biotherapeutics from a sell rating to a hold rating in a report on Friday, December 29th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of Buy and a consensus target price of $26.00.

Atara Biotherapeutics (NASDAQ ATRA) traded up $6.10 during mid-day trading on Thursday, hitting $28.25. The stock had a trading volume of 3,694,300 shares, compared to its average volume of 1,425,811. The company has a market capitalization of $864.33, a P/E ratio of -8.14 and a beta of 1.27. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $30.40.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). sell-side analysts expect that Atara Biotherapeutics will post -4 EPS for the current fiscal year.

In other news, CEO Isaac E. Ciechanover sold 2,200 shares of the company’s stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $15.15, for a total transaction of $33,330.00. Following the completion of the transaction, the chief executive officer now directly owns 743,675 shares of the company’s stock, valued at $11,266,676.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO John Mcgrath sold 37,000 shares of the company’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $24.35, for a total value of $900,950.00. Following the transaction, the chief financial officer now directly owns 93,154 shares of the company’s stock, valued at $2,268,299.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 190,088 shares of company stock valued at $3,795,591. Insiders own 16.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Atara Biotherapeutics during the third quarter worth about $142,000. Russell Investments Group Ltd. acquired a new position in shares of Atara Biotherapeutics during the third quarter worth about $170,000. Voya Investment Management LLC boosted its position in shares of Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,651 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of Atara Biotherapeutics during the second quarter worth about $252,000. Finally, The Manufacturers Life Insurance Company boosted its position in Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 1,369 shares during the last quarter. 69.67% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/15/atara-biotherapeutics-atra-stock-rating-upgraded-by-bidaskclub.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related stocks with our FREE daily email newsletter.